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Objectives: Previous validation of the HIV Treatment Satisfaction Questionnaire status version 
(HIVTSQs) found that 9/10 items performed well, but the demands item needed revision. This study 
investigated the psychometric properties of the revised HIVTSQs and new change version 
(HIVTSQc).   
Methods: English-speaking Americans completed the HIVTSQs at baseline and Week 48 of a clinical 
trial of HIV treatments, and the HIVTSQc at Week 48. Demographic and viral load information was 
collected. Psychometric validation used item frequency distributions, Confirmatory Factor Analysis 
(CFA), item-total correlations, Cronbach’s alpha, Spearman’s rank correlation, Kruskal-Wallis and 
Mann-Whitney tests.  
Results: At baseline, 126/152 patients completed the HIVTSQs fully (100/106 at Week 48). The 
negatively skewed distribution of the revised demands item resembled that of the other nine, with 
comparable missing data. CFA (baseline and Week 48) supported the general satisfaction/clinical 
subscale (alpha 0.83; 0.85), lifestyle/ease subscale including demands (alpha 0.82; 0.85), and ten-
item treatment satisfaction scale (alpha 0.89; 0.91). Subscale and scale scores differed significantly 
between ethnic groups. Viral load was not significantly related to subscale or scale scores.  At Week 
48, 97/106 patients completed the HIVTSQc fully. All items had negatively skewed distributions. CFA 
supported two subscales (general satisfaction/clinical change alpha 0.85; lifestyle/ease change alpha 
0.88) and ten-item treatment satisfaction change scale (alpha 0.92).  Viral load change between 
baseline and Week 48 correlated significantly with patients’ perceptions of change in HIV control 
(control(c) item), but not with scale or subscale scores.   
Conclusions: The excellent psychometric properties of the HIVTSQs and c support their use in 
clinical trials.     250 
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Introduction 
The HIV Treatment Satisfaction Questionnaire (HIVTSQ) was developed to evaluate treatments for 
Human Immunodeficiency Virus (HIV) [1]. It is one of several condition-specific measures using the 
format of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) [2],[3]. Others are for end stage 
renal disease [4], genital herpes [5], diabetic retinopathy [6], and hypothyroidism [7], as well as the
DTSQ-Teen for teenagers with diabetes and DTSQ-Parent for parents of children with diabetes. 
 
In the original validation study, 150 American and Canadian patients completed an earlier version of 
the ten-item HIVTSQ status version (HIVTSQs). Psychometric analyses [1] revealed two subscales 
(the five-item general satisfaction/clinical subscale (range 0-30) and the four-item lifestyle/ease 
subscale (range 0-24)) as well as the total treatment satisfaction scale (range 0-54), computed from 
nine of the ten items. Each scale and subscale had good internal consistency reliability. The 
validation showed that the fourth item, How demanding is your present form of treatment (in terms of 
time, effort, thought etc.)? was problematic. It was the only item for which the least favourable 
response (very demanding) was to the left of the scale, scoring 6 and the most favourable response 
(very undemanding) to the right, scoring 0. For the remaining nine items, the most favourable 
response was to the left. Distributions of nine items were negatively skewed, most patients indicating 
high levels of satisfaction. Scores for the demanding item, however, formed a more rectangular 
distribution, indicating that some patients may have circled responses towards the left, believing 
these to be more favourable, as for the other nine items. Statistical analyses showed that the 
demanding item did not fit into the structure of the measure. Recommendations for computing scores 
therefore excluded this item. The report recommended that the problematic item wording should be 
changed to: How satisfied are you with the demands made by your current treatment? (response 
options very satisfied (6) to the left, to very dissatisfied (0) to the right). The earlier version of the 
HIVTSQs had already been used in two further trials and translated into several languages without 
involvement of its authors. For those language versions with acceptable translations, psychometric 
analyses strongly supported the nine-item treatment satisfaction scale, which proved sensitive to 
differences between treatment groups in three trials [8]. 
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A ‘change’ version of the DTSQ (the DTSQc) has been found valuable in overcoming ceiling effects 
that often arise with status measures of satisfaction, the DTSQs (status) version being no exception. 
Although the DTSQs has proved sensitive to change in many trials (reviews [2],[9]), the DTSQc 
enhances that sensitivity by allowing those who were satisfied at baseline to express even greater 
satisfaction at follow-up [10],[11]. An HIVTSQ change version should prove similarly useful in 
identifying improvements, particularly where ceiling effects are apparent. 
Figure 1 Linguistically validated versions of the HIVTSQs and a change version, the HIVTSQc (Figure 1) were 
therefore prepared in several languages, each with the revised demanding item having the most 
favourable response to the left (now labeled demands, item 4 in each measure). In the present work 
we investigate the structure of the revised HIVTSQs and the new HIVTSQc (English version 
completed in USA) and the internal consistency reliability of any scales/subscales, to determine the 
scoring for each measure, including procedures for dealing with missing values and the relationship 




At baseline (Day 1) of a clinical trial of an investigational product for treatment of HIV, just before 
randomisation to one of three treatments, the HIVTSQs (English version) was administered to 152 
English-speaking American, HIV-positive individuals already receiving antiretroviral therapy. This was 
a different sample from the 150 patients in the previous validation study [1]. At screening, which 
preceded baseline by some weeks, patients eligible to participate in the present trial were 
‘experiencing failure of their antiretroviral therapy regimen’ (plasma HIV-1 RNA ≥1,000 copies/mL). All 
patients who completed at least one HIVTSQ measure during the trial were included, whether or not 
they completed the trial. The HIVTSQc (English) was administered to the 106 patients remaining in 
the trial at Week 48 on randomised treatment. Patients completed the measures themselves, before 
seeing the clinician and before being informed of their viral load. Demographic data, including age, 
gender and ethnicity were recorded, as was viral load at each time point.  
Analysis 
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Demographic and disease characteristics were summarised. The distribution of item scores and 
frequency of missing data were examined. Week 48 HIVTSQc item scores were correlated against 
the difference between HIVTSQs item scores at baseline and Week 48 (computed as Week 48 - 
baseline). Analyses followed broadly the same sequence for both HIVTSQs and c. Confirmatory 
Factor Analysis (CFA) was conducted on baseline and Week 48 HIVTSQs item scores (without and 
then with the demands item),and on all ten HIVTSQc scores, using the maximum likelihood 
estimation algorithm of Amos 4.01, to determine whether the general satisfaction/clinical and 
lifestyle/ease subscales, then the treatment satisfaction scale were supported. A normed fit index 
(NFI) ≥0.9 was considered to indicate an acceptable fit [12, pages 407-8] and standardised 
regression weights >0.4 for contributing items were considered acceptable. In SPSS for Windows 
12.0, corrected item-total correlations (each item correlated with the sum of the remaining items) and 
Cronbach’s alpha were used to determine the internal consistency reliability of scales/subscales 
identified in the CFAs. Alpha >0.7 is usually considered acceptable, though for some purposes, alpha 
>0.8 is desirable. Item-total correlations and alpha with each item removed were examined to identify 
any items not contributing well to the scale, indicated by a relatively poor item-total correlation and an 
increased alpha if that item was removed.  
The method for computing missing values for any scale or subscale involved removing first the item 
whose removal caused the greatest fall in the scale alpha. This is the ‘strongest’ item and internal 
consistency will be damaged most if this item is missed. Cronbach’s alpha was then calculated 
without that item. If the alpha remained above 0.7, the item whose removal now caused the greatest 
fall in the scale alpha was removed and Cronbach’s alpha calculated again without both the strongest 
and second item. The process was repeated cyclically until the scale alpha fell below 0.7. The 
number of items that could be missed, but the scale score still computed using completed items, was 
the number of items remaining in the Cronbach’s alpha analysis before alpha fell below 0.7. The 
number of items that could be missed whilst retaining an alpha >0.8 was also ascertained. In order to 
retain a range of content when judging satisfaction, a maximum of half the items may be missed (e.g. 
five from a ten-item scale), regardless of the alpha achieved.  
Scale and subscale scores were then computed and associations with demographic characteristics 
(age at recruitment, sex and ethnicity) and viral load at that visit were examined. Non-parametric 
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statistics were used to determine whether there were significant demographic differences: Mann-
Whitney U tests compared the two age categories (median split into younger <40 and older ≥40 
years) and the two sexes; Kruskal-Wallis multiple comparison test, backed by Mann-Whitney U tests, 
compared three ethnic groups (Hispanic, African-American, White). In each case, a probability (p) of 
<0.05 (two-tailed) indicated a significant difference between subgroups. Subscale and scale scores 
and control item scores were correlated against viral load (Spearman’s rank correlation). In the case 
of the HIVTSQs, this was viral load at baseline and again at Week 48; in the case of HIVTSQc, it was 
change in viral load between baseline and Week 48, computed as (Week 48 – baseline) so that a 




HIVTSQs Validation  
Demographic and disease characteristics 
Table 1  Table 1 describes the HIVTSQs baseline sample. The majority were men and the average age was 
around 40 years. Just over half were White and 37.5% were African-American. Viral load varied 
considerably, shown by the minimum and maximum values and the fact that the standard deviation 
exceeded the mean.  The viral load distribution was positively skewed, 51.1% with viral load <11,000 
and only 7.1% with viral load >200,000. HIV-1 RNA(log10) is also shown. Although all were 
immunologically compromised when screened for trial participation (HIV-1 RNA ≥1,000 copies/mL), 
twelve had viral loads <1,000 and three had viral loads <400 HIV-1 RNA copies/mL at baseline. One 
scored the lowest possible on the assay (<50, coded as 49).  
Distribution of HIVTSQs item scores 
Scores for every HIVTSQs item, including demands, had a negatively skewed distribution, with a 
greater frequency of responses towards the higher end of the 0-6 scale, indicating generally high 
satisfaction.  Baseline satisfaction scores did, however, include some towards the centre and lower 
end of the scale, as expected for people experiencing failure of antiretroviral therapy. Control item 
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scores most approximated a normal distribution (mode = 4). For the remaining items, the modal score 
was higher (mode = 5 for items 4, 5, 6 and 8; mode = 6 for items 1, 3, 7, 9 and 10).   
HIVTSQs missing values  
 If any item is missed more than the others, the wording may be problematic or the content irrelevant 
to the patient population. 126 people (82.9%) completed the HIVTSQs in full at baseline. Although 10 
missed the HIVTSQs entirely, it is not known whether they were given it to complete. A further 16 
missed some items, but not others (between 1 and 8 items missed) and so had clearly been given the 
HIVTSQs to complete. The items they missed were examined to determine whether the revised 
demands item was missed any more frequently than other items. The number to miss each item 
ranged between 2 (lifestyle) and 9 (understanding). Only 4 missed demands. Demographic 
characteristics of those who missed items were examined. Only 77.2% of African-American people 
completed the HIVTSQs fully, compared with 85.7% Hispanic and 86.3% White people. Those 
missing all ten items were similar demographically to the entire sample: 9 men and 1 woman; 7 
White, 2 African-American and 1 Hispanic; mean age 44.5 (sd 6.3). Of the16 who completed some 
items but not others, however, 11 were African-American and only 4 were White. All those missing 6+ 
items were African-American. Considering the 142 who attempted the HIVTSQs, 69/73 White 
patients, 12/13 Hispanic and the ‘Other’ man completed it fully, but only 44/55 African-American 
patients.  A χ2  test (three ethnic groups (excluding the ‘Other’ man) and two completion categories 
(full versus partial completion)) revealed a significant ethnic difference in completion (χ2 = 6.76; n = 
141; df = 2; p = 0.03).  
HIVTSQs Structure 
Baseline structure  
Table 2 The hypothesised structure found in the original validation [1], with items 1,2,3,9 and 10 loading on 
one factor (general satisfaction/clinical), and items 5-8 loading on the other (lifestyle/ease), was 
tested, allowing for correlation between the two latent variables, using the maximum likelihood 
estimation algorithm in Amos. The fit of the model was good:  Ҳ2 for the solution was 56.81 (df  = 26; 
p<0.001) and Ҳ2/df  = 2.19 and normed fit index (NFI) = 0.98, which exceeds the required value of 0.9 
for goodness of fit. The two latent variables correlated 0.69. When the demands item was added 
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(hypothesised as fitting into the lifestyle/ease subscale),  Ҳ2 was 116.67 (df = 34; p<0.001), Ҳ2/df = 
3.43 and NFI = 0.97. The two latent variables correlated 0.76. In both the nine-item and ten-item 
analysis, nine items had standardised regression weights >0.4, but the weight for understanding was 
slightly lower. Thus, the fit to the model with two five-item subscales (general satisfaction/clinical and 
lifestyle/ease) was acceptable, but understanding did not fit as well as the other items. When the 
goodness of fit of a single nine-item scale model (without demands) was tested, Ҳ2 was 116.73 (df = 
27; p<0.001), Ҳ2/df = 4.32 and NFI = 0.96. Adding in the demands item, Ҳ2 was 167.37 (df = 35; 
p<0.001), Ҳ2/df = 4.78 and NFI = 0.95. In both cases, the standardized regression weight for 
understanding fell just below 0.4, but the weight for demands was strong (0.85) (see Table 2 
summarising the 10-item CFAs) 
 Week 48 structure 
In order to check this structure amongst the same participants but with experience of different trial 
treatments, CFA was performed on data collected in Week 48 for all patients completing the trial on 
randomised treatment (even though some changed their background therapy for reasons of safety or 
intolerance). Because the three treatment groups had different treatment experiences, the following 
check was conducted to determine whether their HIVTSQs scores could be combined for 
psychometric analysis: (i) The raw scores for the ten items were subjected to Principal Components 
analysis (PCA), with a forced single-factor solution. (ii) Within each of the three treatment groups 
separately, normalised scores (z-scores) were computed for each questionnaire item. Combining the 
dataset again, these z-scores were subjected to PCA, with a forced single-factor solution. (iii) The ten 
factor loadings for (i) were regressed against those from (ii) (n = 10). If the regression coefficient is 
close to 1 and the constant close to zero then the three subsets of data can be combined. The 
correlation between the two sets of loadings was very high (R = 0.994), the constant (-0.050) was not 
significantly different from zero [t(8) = 1.57; p>0.05] and the slope (1.061) was not significantly 
different from 1 [t (8) = 1.419; p>0.05]. This indicated that even though the absolute values in each 
treatment group might differ, the inter-relationships between items are similar and the three groups 
can be combined for further analysis. All ten HIVTSQs items (Week 48) were entered into a CFA, to 
determine goodness of fit of the two-subscale model. Ҳ2 was 83.23 (df = 34; p<0.001), Ҳ2/df = 2.45 
and NFI = 0.98, with the two latent variables correlating 0.83. All ten items had standardized 
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regression weights >0.4, though understanding was the weakest at 0.41. Testing the goodness of fit 
of a ten-item single scale model (Week 48), Ҳ2 was 137.95 (df 35; p<0.001), Ҳ2/df = 3.94 and NFI = 
0.97. Nine items had standardized regression weights >0.4, though understanding was exactly 0.4 
(Table 2). 
Internal consistency reliability of two subscales and single scale 
Table 3  Internal consistency reliability analysis was conducted first on baseline data.Table 3 provides the 
corrected item-total correlation for each item and alpha with each item removed (n = 129 who 
completed all five general satisfaction/clinical subscale items, n = 128 for the five lifestyle/ease items 
and n = 126 for the ten treatment satisfaction scale items). The scale alpha for general 
satisfaction/clinical was 0.83, for lifestyle/ease, α was 0.82 and for treatment satisfaction, α was 0.89. 
In each case, all item-total correlations were >0.4. As expected from the CFA, the weakest item was 
understanding in both the general satisfaction/clinical subscale and treatment satisfaction scale. 
Alpha >0.8 confirmed very good internal consistency reliability at Week 48 (general 
satisfaction/clinical α = 0.85; lifestyle/ease α = 0.85 and treatment satisfaction α = 0.91). We conclude 
from these analyses that the general satisfaction/clinical subscale can be computed from items 1,2,3, 
9 and 10 and the lifestyle/ease subscale from items 4-8 (possible range 0-30 for each subscale)  and 
treatment satisfaction scale score can be computed as the sum of all ten HIVTSQs items (possible 
range 0-60), but that understanding is a relatively weak item..  
Dealing with missing HIVTSQs values  
Items were removed cumulatively and alpha calculated again for each subscale and scale at 
baseline. Their removal was not in the exact order expected from the original alpha-if-item-deleted 
values. For example, item 1 was removed from the treatment satisfaction scale before item 5. This is 
because the number of participants contributing to the analysis increased and the content of the scale 
changed with cumulative removal of items. Removing the strongest item (current treatment) from the 
general satisfaction/clinical subscale resulted in a fall to α = 0.767, but removal of the second 
strongest (continue) would result in a fall to 0.681, so only one general satisfaction/clinical item can 
be missed and substitute for with the mean of the remaining four items before the general 
satisfaction/clinical subscale is computed as the sum of the five items. Removing the strongest item 
(convenience) from the lifestyle/ease subscale resulted in a fall to α = 0.742, but removal of the 
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second strongest (lifestyle) would result in a fall to 0.606, so only one lifestyle/ease item can be 
missed and substituted by the mean of the remaining four items before the lifestyle/ease subscale is 
computed as the sum of the five items. Each subscale cannot be computed for those missing more 
than one contributing item. If greater internal consistency reliability of >0.8 is needed, then no missing 
values can be tolerated. Removal of the strongest item from the total treatment satisfaction scale, 
(demands) reduced α to 0.868. Removal also of current treatment reduced α to 0.847, then additional 
removal of convenience reduced α to 0.819. Thus, three items may be missed before alpha falls 
below 0.8. Further removal of recommend to others reduced α to 0.778 and removal of control 
reduced α further to 0.723. Removal of understanding would reduce the scale alpha to 0.705, which 
just exceeds the criterion level of α>0.7. However, in order to retain the range of content of the 
measure when computing missing values, a maximum of five items (half the scale) may be missed 
and each computed as the mean of completed item scores. The treatment satisfaction scale score 
can now be computed as the sum of the ten item scores, including substituted means as necessary 
for up to five items (for α>0.7) or three items (for α>0.8). If six or more items are missed, the scale 
score should not be computed.  
Computing two subscale and scale scores 
 Using the method of computing subscales scores, in which only one missing value is replaced by the 
mean, 136 general satisfaction/clinical subscale scores were computed at baseline (an additional 
seven, compared with the 129 completing all five items). Mean general satisfaction/clinical was 20.6 
(sd 6.7), median and mode 22, ranging 2 to 30 and skewness -0.53 (se 0.21). Using the same 
method for the lifestyle/ease subscale, 137 scores could be computed (compared with 128 
completing all five items). Mean lifestyle/ease was 22.9 (sd 5.6) median and mode 24, ranging 1-30. 
Thus, both subscales provide a range of scores, with a negative skew, the median being greater than 
the mean. Using the method of computing missing values in which up to five missing values can be 
replaced by the mean, baseline treatment satisfaction scores were computed for 139 patients, an 
additional 13 (eight African-American, four White and one Hispanic) compared with the 126 who 
completed the HIVTSQs fully.  Mean treatment satisfaction was 43.5 (sd 11.3); median 45 (ranging 5 
to 60). The mode was 50 (10 below the maximum possible) and skewness -0.66 (se 0.21).  
Examination of subscale and scale scores in relation to demographic variables and viral load  
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Table 4 There was no significant difference between the two age categories or between sexes in general 
satisfaction/clinical, lifestyle/ease or treatment satisfaction, but there was a difference (Kruskal-Wallis) 
between ethnic groups for all three scores (Table 4). At baseline, African-American people reported 
significantly higher general satisfaction/clinical than did White people (Mann-Whitney p = 0.034), 
higher lifestyle/ease (p = 0.011) and higher treatment satisfaction (p = 0.007). The direction of the 
difference is all the more striking when baseline viral load is examined. Although there was no 
significant difference between viral loads of the three ethnic groups (F = 1.82; df 2; p = 0.17), the 
mean viral load for White patients was 38,540.6 HIV-1 RNA copies/mL (sd 91,958.1), whereas for 
African-American patients, it was higher at 77,868.1 (sd 144,729.2), the Hispanic patients having an 
intermediate mean 62,215.4 (sd 97768.7). African-Americans thus had poorer HIV control, yet greater 
satisfaction. 
Baseline viral load was correlated against control item scores (r = -0.14; n = 138; p = 0.09), against 
general satisfaction/clinical (r = -0.12; n = 135; p = 0.16), lifestyle/ease (r = -0.003; n = 136; p = 0.98) 
and treatment satisfaction (r = -0.09; n = 138; p = 0.60). None were significant. At Week 48, however, 
the correlation with viral load was significant for the control item (r = -0.44; n = 102; p<0.001) and for 
general satisfaction/clinical (r = -0.24; n = 101; p = 0.18) whilst remaining non-significant for 
lifestyle/ease (r = 0.001; n = 102; p = 0.99) and treatment satisfaction (r = -0.10; n = 102; p = 0.30). 
Investigation of baseline correlations with viral load for each ethnic group (Hispanic, African-American 
and White) revealed a significant correlation between viral load and the control item for White patients (r 
= -0.23; n = 73; p = 0.046), but this was weaker for African-American people (r = -0.17; n = 51; p = 0.22) 
and negligible for Hispanic patients (0.08; n = 13; p = 0.80). At Week 48, the correlation was more 
strongly significant for White patients (r = -0.42; n = 56; p = 0.001), significant for African-American 
patients (r = -0.48; n = 36; p = 0.003) and followed the same pattern, albeit less strongly, for the much 
smaller sample of Hispanic patients (r = -0.13; n = 9; p = 0.74). The negative correlation between viral 
load and general satisfaction/clinical scores was stronger at Week 48 for African-Americans, (r = -0.34; 
n = 35; p = 0.048) and for White patients (r = -0.17; n=56; p=0.20)  than it had been at baseline (African-
American (r = -0.21; n = 49; p= 0.14); White ( r = -0.10; n = 72; p = 0.38), indicating a stronger 
relationship between patient perceptions of the clinical effectiveness of their treatment and test results 
as the trial progessed.  
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 HIVTSQc Validation 
The analyses below used HIVTSQc data collected at Week 48 from patients completing the trial on 
their randomised treatment.  
Demographic and disease characteristics 
 By Week 48, 45 patients had withdrawn, leaving 107. However, a Hispanic man completed the 
English HIVTSQs at baseline, but US Spanish versions of HIVTSQs and c thereafter, and he is 
therefore excluded from Week 48 HIVTSQc analysis, leaving n=106 (Table 1).  When recruited, the 
subset of the sample providing HIVTSQc data were about a year older than were the larger HIVTSQs 
baseline sample, indicating that younger people may have withdrawn early from the trial. Ethnic 
groups were in similar proportions to the HIVTSQs baseline sample. At Week 48, average viral load 
was lower than in the baseline analysis: 57 patients (54.3% of 105 with viral load results) had the 
minimum level detected by the assay (coded as 49 HIV-1 RNA copies/mL), compared with only one 
person at baseline; furthermore, 83/105 (79%) had a viral load <1,000, compared with 12 at baseline.  
Distribution of HIVTSQc item scores  
Distribution of scores for the ten HIVTSQc items was examined within each of the three treatment 
groups. The distribution for all ten items was negatively skewed, with a modal response of +3 for 
almost all items, indicating the maximum possible degree of improvement (e.g. much more satisfied 
now). The only exceptions were the mode of +2 for side effects(c) in treatment groups 1 and 3, mode 
of +2 for understanding(c) and joint modal score of 2 and 3 for lifestyle(c) in treatment group 1. The 
minimum score for control(c) was zero for all three treatment groups, indicating that all patients 
thought their HIV control was either as good as before the trial, or better. However, for each of the 
other nine items, a few patients indicated a negative change. For demands(c), flexibility(c), lifestyle(c) 
and recommend to others(c), there were negative changes for at least one person in each treatment 
group, indicating a belief that the trial treatment was less satisfactory than their previous treatment. 
Spearman’s correlation between Week 48 change item scores and the difference between status 
scores obtained at baseline and Week 48 were all positive (ranging between r = +0.12 and +0.39). 
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Five correlations were significant (p<0.05), indicating that change judgments related to differences in 
absolute judgments of satisfaction, though not very strongly. 
HIVTSQc missing values  
Of the 106 who attended at Week 48,, only nine missed any HIVTSQc items, of whom two missed the 
entire measure. It is not certain that those two were given the HIVTSQc to complete. However, the 
seven people missing 1-9 items clearly had received the measure and each item was missed by 
between 2 and 4 of these people. Thus, no item was missed any more frequently than another. Whilst 
56 (98.2%) White patients and the ‘Other’ ethnicity patient completed the measure fully, only 8 
(88.9%) Hispanic and 32 (82.1%) African-American patients did so. 
HIVTSQc Structure  
Because the three treatment groups had different treatment experiences, the raw-score z-score 
check was conducted to determine whether their HIVTSQc scores could be combined for 
psychometric analysis, as described above for the Week 48 HIVTSQs data. The correlation between 
the two sets of loadings was very high (R = 0.995), the constant (-0.041) was not significantly different 
from zero [t(8) = 1.530; p>0.05] and the slope (0.950) was not significantly different from 1 [t (8) =  
-1.429; p>0.05]. This indicated that even though the absolute values in each group might differ, the 
inter-relationships between the items are similar and the three treatment groups can be combined for 
further analysis.  
Table 5 CFA first sought to confirm the two-subscale model, by including all ten item scores in the analysis, 
with intercorrelation between the two latent variables. Each HIVTSQc change item was allocated to 
the same subscale as for the status version. Ҳ2 was 193.60 (df  = 34; p<0.001), Ҳ2/df  = 5.69 and NFI 
= 0.92 and the two latent variables correlated 0.85. For a single ten-item treatment satisfaction 
change scale (all items loading onto one latent variable), Ҳ2 was 257.03 (df = 35; p<0.001) Ҳ2/df = 
7.34 and NFI = 0.90, which is just acceptable. For both the two-subscale and single scale model, all 
ten standardised regression weights were >0.4 (Table 5). 
Internal consistency reliability of the treatment satisfaction change scale 
Table 6 The internal consistency reliability of each of the the five-item subscales (general satisfaction/clinical 
change and lifestyle/ease change) and the ten-item treatment satisfaction change scale was tested, 
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using corrected item-total correlations and Cronbach’s alpha statistics. Table 6 provides the item-total 
correlation for each item and alpha if each item is removed (n = 98 for each of the two subscales and 
n = 97 for the treatment satisfaction change scale, having completed all HIVTSQc items within the 
relevant scale/subscale at Week 48). The scale alpha for general satisfaction/clinical change was 
0.85, the strongest item being continue(c); for lifestyle/ease change, alpha was 0.88, the strongest 
item being lifestyle(c) and for treatment satisfaction change, alpha was 0.92, the strongest item again 
being continue(c). The demands(c) item fitted well into both the lifestyle/ease change subscale and 
the total treatment satisfaction change scale. The items least integral to the treatment satisfaction 
change scale were control(c) and understanding(c). Alpha increased when control(c) was removed 
from the general satisfaction/clinical change subscale and when understanding(c)_was removed from 
the lifestyle/ease change subscale. The  general satisfaction/clinical change subscale can be 
computed as the sum of change items 1,2,3,9 and 10, the lifestyle/ease change subscale computed 
as the sum of change items 4-8 (possible range -15 to +15) and the treatment satisfaction change 
score computed as the sum of all ten HIVTSQc items, (possible range +30 to -30). The higher the 
positive score, the greater is the improvement in satisfaction since the start of the trial. The more 
negative the score, the greater is the deterioration in satisfaction. 
Dealing with missing HIVTSQc values 
In the general satisfaction/clinical change subscale, removal of the strongest item (continue(c)) 
caused alpha to fall to 0.768, but removal also of current treatment(c) would cause too great a fall to 
0.548. In the lifestyle/ease change subscale, removal of the strongest item, lifestyle(c), caused alpha 
to fall to 0.824, but removal then of item 6 (flexibility(c)) caused a fall to 0.696, (just below the 0.7 
desired minimum). Therefore, only one item may be missed from each of the subscales and 
substituted by the mean of the four remaining items before summing all five to produce the relevant 
subscale score. Subscale scores cannot be computed for those missing more than one item from the 
subscale concerned. To retain an alpha >0.8, no missing items can be tolerated in either subscale. 
Removal of the strongest item from the treatment satisfaction change scale,, lifestyle(c), reduced 
alpha to 0.897. The additional removal of continue(c) reduced it to 0.862, removal also of flexibility(c) 
reduced it to 0.829 and removal also of current treatment(c) reduced it to 0.801 (still above the higher 
criterion of 0.8). Removal of demands(c) reduced it considerably to 0.718. Removal of 
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understanding(c) would reduce it to 0.707, still above the criterion level of 0.7. However, in order to 
retain the range of content, only five items may be missed and each can be substituted by the mean 
of completed items (maximum of four items to retain alpha >0.8). The treatment satisfaction change 
score can then be computed as the sum of the ten item scores, using substituted means where 
necessary. If six or more items are missed, the scale score cannot be computed.  
Computing subscale and scale change scores 
 Week 48 general satisfaction/clinical change and lifestyle/ease change scores were computed, using 
the method of substituting up to  one missing value.  For general satisfaction/clinical change, 99 
scores were computed (one more than the 98 completing all five items). Mean general 
satisfaction/clinical change was 11.5 (sd 4.3), median 13, ranging from -5.0 to +15.0; mode +15 (the 
maximum possible positive change) and skewness -2.26 (se 0.24). For lifestyle/ease change, 100 
scores were computed (two more than the 98 completing all five items). Mean lifestyle/ease change 
was 10.8 (sd 4.8), median 12, ranging from -6.0 to +15.0; mode +15 (the greatest possible positive 
change) and skewness -1.56 (se 0.24).  Treatment satisfaction change scores, using the method of 
substituting up to a maximum of five missing values, could be computed for 100 patients (the 97 who 
completed the HIVTSQc in full, and the additional three who missed either one or two items. The 
mean treatment satisfaction change score was 22.6 (sd 8.6); median 26.0 (ranging -8.3 to +30). The 
distribution was negatively skewed (skewness -1.88 (se 0.2)) with a mode of +30 (the maximum 
possible positive change). Thus, both subscale and scale scores were skewed considerably. 
Examination of subscale and scale change scores in relation to demographic variables and 
viral load  
Table 7 There were no significant age, sex or ethnic differences in HIVTSQc general satisfaction/clinical 
change, lifestyle/ease change or treatment satisfaction change scores (Table 7). The correlation 
between change in viral load from baseline to Week 48 and control(c) item scores was small but 
significant (r = -0.23; n = 93; p = 0.03). The correlations between change in viral load from baseline to 
Week 48 and the Week 48 HIVTSQc subscale/scale scores were, however, negligible  (general 
satisfaction/clinical change (r = -0.08; n = 92; p = 0.48) lifestyle/ease change (r = -0.02; n = 93; p = 
0.84) and treatment satisfaction change (r = -0.03; n = 93; p = 0.75)). . Correlations were conducted 
within each ethnic group between viral load change on the one hand and the control(c) item and 
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subscale and scale scores on the other. The strength of association between control(c) and viral load 
change again differed between ethnic groups. It was significant amongst White (r = -0.37; n = 51; p = 
0.007) but not African-American patients (r = -0.18; n = 32; p = 0.33). Amongst Hispanic patients, 
there was no association (r = 0.01; n = 9; p = 0.98). None of the correlations between viral load 
change and the scale and subscale scores were significant.   
 
Discussion 
The modification to the HIVTSQs has meant that a ten-item treatment satisfaction scale score with 
very good internal consistency reliability can be computed, including an important item concerning the 
demands of treatment. In addition, the two subscales, measuring general satisfaction/clinical aspects 
of treatment and satisfaction with lifestyle/ease of taking the treatment can also be computed, the 
latter including the new demands item. The new HIVTSQc also has a two-subscale structure, 
producing the general satisfaction/clinical change and lifestyle/ease change subscales, as well as a 
single-scale structure, producing the treatment satisfaction change score. All have excellent internal 
consistency reliability. For each measure, the subscale scores are each computed from five items 
and the scale score as the sum of all ten items, rendering trial analysis and interpretation of results 
straightforward.  
The modified wording of the HIVTSQs demands item appears to have solved the problem identified 
with the earlier version. Now, all items have a similar, negatively skewed distribution. The control item 
approximated more closely a normal distribution at baseline, perhaps because patients were recruited 
as experiencing compromised immunity on pre-trial medication. The previous study by Woodcock and 
Bradley [1] found the HIVTSQs to be acceptable to patients who had been taking randomised 
medication for 8 or 16 weeks. In the present study, full completion at baseline by 82.9% of 
participants indicates that it is acceptable also to people at the start of a trial, in which some form of 
anti-HIV treatment was being used before the trial began. Distributions of the HIVTSQc item scores 
were also negatively skewed. Thus, the majority of patients found their treatment more satisfactory at 
Week 48 than at baseline. However, some found their trial treatment less satisfactory in certain 
respects, indicated by negative item scores on the scale +3 to -3. Possibly, before the trial, some 
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patients were not monitored as closely, nor were they given such strict instructions about medication-
taking as they were for the trial. This may in part explain why the trial treatments were seen by some 
as presenting more demands, beings less flexible, and interfering more with lifestyle, so they might 
not recommend them to others as much as they did the pre-trial treatments.  
The completion rate was very good for both measures. It is not known why some people did not 
complete the measures at all, but their demographic characteristics were similar to those of the whole 
sample, suggesting that non-completion may have been driven by study staff, rather than patient 
characteristics. Interestingly, amongst those actually attempting the HIVTSQs, African-American 
people were less likely to complete it in full.  
In determining the structure of the HIVTSQs and c, the HIVTSQs ten-item treatment satisfaction scale 
was strongly supported (scale alpha baseline = 0.89; Week 48 = 0.91) as was the HIVTSQc ten-item 
treatment satisfaction change scale (Week 48 scale alpha = 0.92). These alphas were even higher 
than found for the nine-item scale in the original validation of the status version [1] (Week 8 or 16 α = 
0.82 in full sample of Americans and Canadians; α = 0.80 in USA data). Moreover, the subscales for 
both the HIVTSQs and c had alphas >0.8, at baseline and Week 48, again higher than in the original 
study (general satisfaction/clinical α = 0.80 in USA/Canada; 0.77 in USA alone; lifestyle/ease α = 0.74 
in USA/ Canada; 0.75 in USA). The weakest item generally, as demonstrated by standardised 
regression weights and Cronbach’s alpha, concerned ‘understanding of your HIV’. It may be 
necessary to change the wording of this item in future, possibly to focus on ‘understanding of your 
treatment’, as included in our two recently-developed measures of treatment satisfaction in paediatric 
diabetes, for completion by parents and by teenagers (the DTSQ-Parent and DTSQ-Teen). 
Within the HIVTSQs, the revised demands item was the strongest item in the treatment satisfaction 
scale.  Because of the high internal consistency reliability of both the treatment satisfaction scale and 
the treatment satisfaction change scale, up to five items may be missed from the scale, while still 
computing the scale score  The subscales can each be computed when only one item is missed. This 
method of computing missing values assumes that items are missed at random and that they all 
measure a single underlying latent construct. In some trials using the earlier version of the HIVTSQs, 
the nine-item total treatment satisfaction scores (ranging 0-54) were converted to percentages (0-
100) (Jordan et al) [8]. The same could be done with the ten-item total treatment satisfaction scores 
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(0-60), at the discretion of those using the measure. Whilst this facilitates interpretation, it tends to 
inflate any apparent differences between patient groups. A greater apparent inflation would result 
from changing HIVTSQs subscale scores (range 0-30) into percentages and when translating 
HIVTSQc scale scores (-30 through zero to +30) or subscale scores (-15 through zero to +15) to 
percentage differences from zero (-100% to +100% satisfaction). The skewed distribution of scale 
and subscale scores, particularly those from the change version, indicates that non-parametric 
statistics may be appropriate. Alternatively, ranked data may be used, or measures can be taken to 
normalise the skew before analysis using parametric methods. With large sample sizes, there may be 
very little difference between the results of non-parametric and parametric analyses, but it is 
advisable to check. Two years between baseline and follow-up is a long time for people to make 
HIVTSQc change judgments. The fact that HIVTSQc item change scores all correlated positively with 
the difference between status scores obtained at baseline and Week 48 provides some evidence that 
meaningful judgments were being made, though the HIVTSQc might best be administered after a 
shorter time period (6 or 12 months into a trial) to enable respondents to recall more clearly their 
experience of the previous treatment. 
Some degree of construct validity has already been established for the HIVTSQs, by comparing 
treatments with more/less complex regimens [1]. The present study confirmed a relationship between 
viral load and control item scores, in both the status and change measures, and a relationship 
between the general satisfaction/clinical subscale and viral load at Week 48. In contrast, the 
lifestyle/ease subscale did not correlate with viral load at the same timepoint, indicating that the two 
subscales may be useful in discriminating between treatments with similar effects on clinical status, 
but easier/more difficult to take. Interestingly, the scale scores were not correlated with viral load (or 
viral load change). Thus, overall satisfaction is not simply a matter of controlling clinical status. 
Indeed, if viral load and satisfaction correlated strongly, there would be no need to measure 
satisfaction with treatment. Patients’ perceptions, including convenience, and their understanding of 
test results can also influence satisfaction levels.  
Ethnicity, viral load and treatment satisfaction 
If HIVTSQs general satisfaction/clinical, lifestyle/ease and treatment satisfaction scores were directly 
related to clinical status, it would be expected that African-American people in this trial would be less 
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satisfied than Whites, because their HIV status was somewhat worse. The counterintuitive finding, 
that African-American people reported greater baseline satisfaction on both the subscales and the 
total scale, indicates that the observed ethnic group difference may be cultural rather than a reflection 
of different levels of disease progression. Greater treatment satisfaction amongst non-Whites was 
found in the earlier HIVTSQ validation [1] and contrasts with studies in which non-Whites tend to be 
either less satisfied with medical care than Whites [13],[14] (1996 data), [15] or equally satisfied 
[16],[14] (2000 data). The prevalence of non-White and particularly African-American people amongst 
those attending their Week 48 appointment yet missing HIVTSQc items is notable, especially 
because African-American people tended to report greater baseline satisfaction on the HIVTSQs. It is 
important to use the recommendations for dealing with missing values to compute subscale and scale 
scores for as many people as possible without damage to reliability at follow-up points, when drop-
outs or missing data can undermine randomisation.  
The correlation between viral load and HIVTSQs scores in the original study [1] was r = -0.28 with 
treatment satisfaction and r = -0.33 with the control item (both small but highly significant). Those 
patients were recruited with plasma viral load at least 400 HIV-1 RNA copies/mL and their baseline 
mean viral load was 4.10 copies HIV-1RNA/mL(log10)(sd 0.76). By the week of HIVTSQ completion 
(Week 8 or 16), however, their mean viral load was down to 3.10 (sd 0.85).  Baseline mean viral load 
in the present study, transformed to a log10 scale, was 4.09 (sd 0.82). Thus, the viral load at the start 
of the two trials was very similar. At baseline of the present study, however, neither the treatment 
satisfaction scale score nor the control item score correlated significantly with baseline viral load. 
There are two possible reasons for this difference between the two studies.  In the earlier study, 
which collected data 8 or 16 weeks into the trial, patients would by that time be familiar with viral load 
reporting and might have based their perceptions of HIV control on those readings; also, the trial 
protocol of the earlier study did not dictate when to administer the HIVTSQs in relation to viral load 
reporting and some patients may have known their results before completing the questionnaire. In the 
present study, however, all patients completed the HIVTSQs before receiving their test results and so 
a weaker correlation between HIVTSQs scores and viral load might be expected. Patients would rely 
on their perceptions of HIV control, which would be hard, particularly for asymptomatic patients. Viral 
load spanned a large range and may have included symptomatic as well as relatively symptom-free 
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patients. Correlations between HIVTSQs control item scores and viral load at baseline and Week 48 
support the suggestion that participation in the trial increased understanding of viral load results, 
which affected ratings of the control item. They also suggest that African-American and particularly 
Hispanic participants had less information about their viral loads at baseline, possibly diluting the 
association between viral load and control item responses in the full sample. The correlation was 
significant amongst White participants at baseline and became significant in the combined sample by 
Week 48. Correlations between HIVTSQs control item scores and viral load at baseline and Week 48 
support the suggestion that participation in the trial increased understanding of viral load results, 
which affected ratings of the control item.  
For the HIVTSQc, there was no ethnic difference in subscale or scale scores, but the means 
indicated a tendency for African-American people to indicate the greatest improvement in satisfaction. 
Correlations showed that particularly White and, to a lesser extent, African-American respondents 
whose viral load had improved more by the close of the trial reported a greater increase in 
satisfaction on the HIVTSQc control(c) item. Despite a tendency for a similar relationship between 
total treatment satisfaction change and viral load change, the negative correlation was not significant 
and the correlation with the subscale scores was small in each case. The stronger correlation with 
control(c) is to be expected, because this is the one item out of the ten that is likely to relate directly to 
viral load and physical outcomes. This association provides preliminary evidence of construct validity 
of the HIVTSQc. The stronger correlation between viral load change and HIVTSQc control(c) scores 
for White patients compared with African-American or Hispanic patients suggests again that White 
participants might have had more information about their viral load and used this when responding to 
the control(c) item. This finding has implications for the education of people infected with HIV, but 
requires further investigation due to the small number of Hispanic patients in the present study.  
Because of the complex relationships identified between ethnicity, understanding of viral load results 
and perceptions of HIV control, ethnicity could usefully be included as a potential confounding 
variable (covariate) in trial analyses of HIVTSQs and c data. This is in addition to ensuring that ethnic 
groups are similarly represented in each treatment group at recruitment, because African-Americans 
may also be rather more likely than other Americans to miss items. If a scale score cannot be 
computed for them at any point during the trial, due to missing several items, this could potentially 
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exclude patients indicating higher satisfaction levels from trial analyses. It is also advisable to include 
baseline HIVTSQs scores as a covariate to deal with any potential confounding influence on 
HIVTSQc scores later in the trial. The less satisfied people are when they begin the trial, the more 
room there will be for improvement.  
These two measures are already available in several languages, produced using two independent 
forward translations, reconciliation, and two back translations, with revision and further back 
translation as needed. Further work will include assessment of the equivalence of completion 
methods, such as pen and paper compared with telephone administration, further linguistic validation 
of translations, including full cognitive debriefing with patients, as well as analysis of sensitivity to 
differences between treatments. 
 
Conclusion 
The HIVTSQs and c each has a structure with two five-item subscales, measuring general 
satisfaction/clinical and lifestyle/ease satisfaction. A ten-item treatment satisfaction scale may also be 
computed for each measure. The HIVTSQs subscale and scale scores can be used at baseline and 
later in the trial to make comparisons between groups and over time. The HIVTSQc subscale and 
scale scores allow an improvement to be expressed later in the trial, even by patients with high levels 
of satisfaction at baseline. The subscales and scales in both measures have very good internal 
consistency reliability. The control item score from each measure correlates with viral load more 
strongly than does the scale score and this relationship becomes stronger during a trial, suggesting 
that understanding of viral load results may improve during a trial. Together, the HIVTSQs and c can 
be used in trials of new HIV treatments, to provide insight into patients’ perspectives, which are not as 
closely related to viral load as might be expected. 
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Figure 1. Item content of the HIVTSQs and HIVTSQc 
 
 HIVTSQs: HIVTSQc 
   Instructions 
The following questions are concerned with your 
anti-HIV medicine therapy for HIV infection and your 
experience over the past few weeks.  Please answer 
each question by circling a number on each of the 
scales. 
Instructions 
The following questions are concerned with your present anti-
HIV medicine therapy compared with your experience of 
medicine therapy used just before you started in the current 
study. We are interested to know how, if at all, your experience 
of medicine therapy has changed. Please answer each 
question by circling a number on each of the scales to indicate 
the extent to which you have experienced changes. If you have 
experienced no change, circle ‘0’. 
Item 
no. 
Item label  
[Suffix (c) denotes 
item label in the 
change version] 
Item wording Response options 6-0 Response options 6-0 
1 current treatment How satisfied are you with your current 
treatment?  
very satisfied 6 to 0 very dissatisfied much more satisfied now 3 to -3 much less satisfied now 
2 control How well controlled do you feel your HIV 
has been recently? 
very well controlled 6 to 0 very poorly controlled much better controlled now 3 to -3 much worse controlled now 
3 side effects How satisfied are you with any side-effects 
of your present treatment? 
very satisfied 6 to 0 very dissatisfied much more satisfied now 3 to -3 much less satisfied now 
4 demands How satisfied are you with the demands 
made by your current treatment?   
very satisfied 6 to 0 very dissatisfied much more satisfied now 3 to -3 much less satisfied now 
5 convenience How convenient have you been finding 
your treatment to be recently? 
very convenient 6 to 0 very inconvenient much more convenient now 3 to -3 much less convenient now 
6 flexibility How flexible have you been finding your 
treatment to be recently? 
very flexible 6 to 0  very inflexible much more flexible now 3 to -3 much less flexible now 
7 understanding How satisfied are you with your 
understanding of your HIV? 
very satisfied 6 to 0 very dissatisfied much more satisfied now 3 to -3 much less satisfied now 
8 lifestyle How satisfied are you with the extent to 
which the treatment fits in with your life-
style? 
very satisfied 6 to 0 very dissatisfied much more satisfied now 3 to -3 much less satisfied now 
9 recommend to 
others 
Would you recommend your present 
treatment to someone else with HIV? 
Yes I would definitely recommend the treatment 6 to 
0 No I would definitely not recommend the treatment 
much more satisfied now 3 to -3 much less satisfied now 
10 continue How satisfied would you be to continue 
with your present form of treatment? 
very satisfied 6 to 0 very dissatisfied much more likely to recommend the treatment now 3 
to -3 much less likely to recommend the treatment now 
Please make sure that you have circled one number on each of the scales. 
 0 
 0 
Table 1. Demographic characteristics, treatment group and viral load of patients included in baseline analysis of HIVTSQs data and Week 48 
analysis of HIVTSQs and HIVTSQc data 
 
 Baseline sample Week 48 sample 
Characteristic n Frequency  
(% of sample)  
Mean (sd) Median (min-max) n Frequency 
(% of 
sample) 
mean (sd) median (min-
max) 





129 (84.9%)  
  23 (15.1%) 
  106  










57 (37.5%)        
80 (52.6%) 
  1 (0.7%) 
     
  9  (8.5%) 
39 (36.8%) 
57 (53.8%) 










47 (30.9%)  
50 (32.9%) 
  106  
 
34  (32.1%) 
34  (32.1%) 
38  (35.8%) 
  










   
 




















141  4.09 (0.82) 4.04 (1.69-5.78) 105  2.34 (1.10) 1.69 (1.69-5.83) 
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Table 2. Confirmatory Factor Analysis (CFA) of the ten HIVTSQs items (baseline and Week 48).  
   (showing standardised regression weights for each variable and normed fit index (NFI) for the model.) 
 
Item Baseline 
2 latent variables 
Baseline 
Single latent variable 
Week 48 
2 latent variables 
Week 48 











Total treatment satisfaction 
scale 
 NFI = 0.97 NFI = 0.95 NFI =0.98 NFI = 0.97 
1. current treatment 0.846  0.725 0.914  0.798 
2. control 0.767  0.671 0.767  0.665 
3. side effects 0.514  0.595 0.800  0.693 
4. demands  0.853 0.861  0.879 0.876 
5. convenience  0.894 0.812  0.950 0.923 
6. flexibility  0.654 0.632  0.669 0.675 
7. understanding  0.378 0.368  0.409 0.400 
8. lifestyle  0.720 0.661  0.882 0.859 
9. recommend to others 0.634  0.693 0.693  0.705 




Table 3.   Internal consistency reliability of HIVTSQs subscales and scale (baseline). 
 
Item General satisfaction/clinical subscale 
scale alpha = 0.831 
Lifestyle/ease subscale 
scale alpha =0.821 
Total treatment satisfaction scale 












if item deleted 
1. current treatment      0.74 0.767   0.68 0.876 
2. control 0.67 0.788   0.67 0.877 
3. side effects 0.46 0.845   0.54 0.887 
4. demands   0.66 0.775 0.79 0.868 
5. convenience   0.77 0.742 0.73 0.876 
6. flexibility   0.55 0.812 0.56 0.885 
7. understanding   0.43 0.834 0.40 0.893 
8. lifestyle   0.71 0.758 0.66 0.878 
9. recommend to others 0.60 0.806   0.69 0.876 
10 continue 0.71 0.774   0.65 0.879 
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Table 4. HIVTSQs subscale and scale scores of demographic subgroups (baseline) 
Characteristic 
(for test used, see footnote T) 
Subgroups of patients compared 




    
Age category 
 
Younger     (n=66)  
Mean 20.1 (6.8) 
Median 21 (2-30) 
Older          (n=70)  
Mean 21.2 (6.7) 
Median 22 (4-30) 
 p = 0.33 
Sex 
 
Men            (n=116) 
Mean    20.4(6.7) 
Median 21.5(2-30) 
Women       (n=20) 
Mean 22.0(6.7) 
Median 22.3(4-30) 
 p = 0.29 
Ethnicity¥ Hispanic      (n=13)  
Mean    22.5(6.5) 
Median 23 (10-29) 
African-American  (n=50 )  
Mean        22.0      (6.9) 
Median     23     (4-30) 
White           (n=72) 
Mean    19.4 (6.5) 
Median  20.5 (2-30) 
p = 0.03 
 Hispanic   African-American  p = 0.98 
 Hispanic    White  p = 0.09 
  African-American White  p = 0.02 
Lifestyle/ease subscale     
Age category 
 
Younger     (n=66 )  
Mean  23.1 (5.4) 
Median  24   (8-30) 
Older          (n=71 )  
Mean 22.6 (5.8) 
Median  24 (1-30) 
 p = 0.71 
Sex 
 
Men            (n=117) 
Mean  23.1 (5.4) 
Median  24   (8-30) 
Women       (n=20) 
Mean    21.6(6.8) 
Median  23.0(1-29) 
 p = 0.33 
Ethnicity¥ Hispanic      (n=13)  
Mean 24.4 (6.1) 
Median 27 (11.25-30) 
African-American  (n=50 )  
Mean  24.1 (5.6) 
Median  25 (1-30) 
White           (n=73 ) 
Mean    21.9  (5.3) 
Median 23  (8-30) 
p = 0.01 
 Hispanic African-American  p = 0.53 
Hispanic    White  p = 0.08  
 African-American White  p = 0.006 
Total satisfaction scale     
Age category 
 
Younger     (n= 68)  
Mean 43.2  (10.8) 
Median 11.0 (17-60) 
Older          (n= 71)  
Mean 43.7  (11.76) 
Median 16.0  (5-60) 
 p = 0.64 
Sex 
 
Men            (n=119) 
Mean 43.4  (11.1) 
Median 45.0 (16-60) 
Women       (n=20) 
Mean 43.6   (12.4) 
Median 44.5 (5-58.9) 
 p = 0.86 
Ethnicity¥ Hispanic      (n=13)  
Mean   47.0 (11.0) 
Median 52.0 (27-58) 
African-American  (n= 52)  
Mean 46.0            (11.53) 
Median 47.5         (5-60) 
White          (n= 73) 
Mean   41.2 (10.7) 
Median 43.0(17-60) 
p = 0.014 
 Hispanic   African-American  p = 0.90 
Hispanic  White  p = 0.07 
 African-American White  p = 0.007 
 
    
T Mann-Whitney to compare two age categories (median split at 40 years) and to compare men and women. Kruskal-Wallis (with χ2) to compare three ethic groups, followed by Mann-
Whitney between pairs of ethnic group. ¥’’Other’ ethnicity (n=1) not included in analyses, due to insufficient number of cases. 
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Table 5. Confirmatory Factor Analysis (CFA) of the ten HIVTSQc items (Week 48) 
(showing standardised regression weights for each variable and normed fit index (NFI) for the model.) 
 







satisfaction change scale 
 NFI = 0.92 NFI = 0.90 
1. current treatment(c)    0.863  0.815 
2. control(c)    0.403  0.437 
3. side effects(c)    0.611  0.649 
4. demands(c)     0.832 0.841 
5. convenience(c)     0.821 0.761 
6. flexibility(c)     0.819 0.795 
7. understanding(c)     0.478 0.480 
8. lifestyle(c)     0.951 0.912 
9. recommend to others(c)    0.759  0.686 




Table 6. Internal consistency reliability of the HIVTSQc subscales and scale (Week 48). 
 
Item General satisfaction/clinical 
subscale 
scale alpha =0.850 
Lifestyle/ease 
subscale 
scale alpha =0.882 
Total satisfaction change  
scale 
















if item deleted 
1. current treatment(c)    0.83 0.78   0.77 0.903 
2. control(c)    0.40 0.88   0.38 0.921 
3. side effects(c)    0.59 0.84   0.59 0.912 
4. demands(c)      0.73 0.859 0.79 0.903 
5. convenience(c)      0.74 0.852 0.69 0.907 
6. flexibility(c)      0.82 0.830 0.77 0.903 
7. understanding(c)      0.50 0.904 0.52 0.917 
8. lifestyle(c)      0.84 0.824 0.84 0.897 
9. recommend to others(c)    0.67 0.92   0.71 0.906 
10. continue(c)    0.84 0.77   0.84 0.898 
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Table 7. HIVTSQc treatment satisfaction change scores of demographic subgroups (Week 48) 
 
Characteristic 
(for test used, see footnote T) 
Subgroups of patients compared, with number in subgroup (n) 
HIVTSQc subscale/scale score 








Younger  (n=40)  
Mean 12.8 (2.3) 
Median 14 (6 to 15) 
Older  (n=59)  
Mean     11.2 (5.2) 
Median  13         (-5 to 15)




Men  (n=88) 
Mean 11.7 (4.5) 
Median 13 (-5 to 15) 
Women  (n=11) 
Mean      13.3  (1.8) 
Median   14        (10 to15) 
 p = 0.41 
Ethnicity¥ Hispanic   (n=9)  
Mean    9.9(7.8) 
Median 14 (-5 to15 ) 
African-American (n=33)  
Mean      12.3 (4.0) 
Median   14        (-4 to 15)
White  (n=56) 
Mean    11.9 (3.7) 
Median 13 (-3 to 15) 
p = 0.56 
 




Younger  (n=40)  
Mean 10.7 (4.4) 
Median 11 (-6 to 15) 
Older  (n=60)  
Mean      10.9 (5.1) 
Median   13        (-4 to 15)




Men  (n=89) 
Mean 10.7 (4.9) 
Median 12 (-6 to 15) 
Women  (n=11) 
Mean      11.5  (4.1) 
Median   13.8      (4 to 15) 
 p = 0.56 
Ethnicity¥ Hispanic   (n=9)  
Mean 10.1 (6.3) 
Median 14 (-2.5 to15) 
African-American (n=34)  
Mean     11.8 (4.6) 
Median  14   (-4 to 15) 
White  (n=56) 
Mean    10.4 (4.6) 
Median 11 (-6 to 15) 
p = 0.22 
 
Treatment satisfaction change 
scale 




Younger  (n=40)  
Mean 23.5 (5.9) 
Median 24 (6 to 30) 
Older  (n=60)  
Mean     22.0  (10.0) 
Median  26 (-8.26 to 30) 




Men  (n=89) 
Mean 22.3 (8.9) 
Median 26 (-8.26 to 30) 
Women  (n=11) 
Mean    24.8  (5.4) 
Median 27.8      (17 to 30) 
 p = 0.47 
Ethnicity¥ Hispanic   (n=9)  
Mean 19.9 (14.4) 
Median 27 (-8.26 to 30) 
African-American (n=34)  
Mean    24.0  (8.3) 
Median 27.9       (-8 to 30)
White  (n=56) 
Mean    22.3 (7.6) 
Median 23.5 (-3 to 30) 
p = 0.25 
 
 
T Mann-Whitney U to compare two age categories (with median split at 40 years) and to compare men and women.  Kruskal-Wallis (with χ2) to compare three ethic 
groups.¥ ‘Other’ ethnicity (n=1) not included in analysis due to insufficient number of cases. Post-hoc Mann Whitney not conducted if Kruskal-Wallis not significant 
 Access to Questionnaires 
The HIVTSQs and c are available from the copyright holder, Prof Clare Bradley: c.bradley@rhul.ac.uk 
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